<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772016</url>
  </required_header>
  <id_info>
    <org_study_id>TH-1</org_study_id>
    <nct_id>NCT02772016</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanfang Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</source>
  <brief_summary>
    <textblock>
      Seventy-two pregnant patients diagnosed of minor or intermediate beta thalassemia with mild
      anemia were randomly assigned to treatment group and control group. Patients in the treatment
      group were given 15 g of Colla corii asini in powder form daily for 4 weeks while the control
      group were observed and followed up in the same period without any treatments. Levels of
      hemoglobin(Hb), serum iron (SI), serum ferritin (SF) and three types of hemoglobin components
      [adult hemoglobin (HbA), fetal hemoglobin (HbF), minor adult hemoglobin (HbA2)] were measured
      before and after treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin(Hb)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of hemoglobin(g/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adult hemoglobin(HbA)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of adult hemoglobin(%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal hemoglobin(HbF)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of fetal hemoglobin(%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minor adult hemoglobin(HbA2)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of minor adult hemoglobin(%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum iron(SI)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of serum iron (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin(SF)</measure>
    <time_frame>Four weeks</time_frame>
    <description>the change of serum ferritin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>total white blood count(×109/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>platelet count(×109/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>percentage of neutrophil(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>serum alanine aminotransferase(U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>serum aspartate aminotransferase(U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>urea nitrogen (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Four weeks</time_frame>
    <description>serum creatinine(umol/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in control groups do not receive any intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colla corii asini</intervention_name>
    <description>15 g of Colla corii asini in powder form daily for 4 weeks</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women diagnosed as thalassemia carriers by genetic test with clinical
             presentation of minor or intermediate β- thalassemia;

          -  patients with mild anemia (80 g/L≤ Hb&lt;110 g/L) prior to study enrollment;

          -  singleton pregnancy;

          -  patients having not received blood transfusion or any forms of anti-anemia treatment
             in Western Medicine or Traditional Chinese Medicine in the last 12 weeks;

          -  informed consent obtained.

        Exclusion Criteria:

          -  patients with severe thalassemia;

          -  patients with severe anemia (Hb&lt;80 g/L) prior to study enrollment;

          -  twin or multiple pregnancies;

          -  patients with any of the following abnormalities: immunodeficiency, primary diseases
             involving cardiovascular system, liver, kidney, gastrointestinal tract, endocrine
             system and hematological system;

          -  allergic to two or more drugs;

          -  patients with mental illness or poor compliance to medical treatment;

          -  patients having received blood transfusion or any forms of anti-anemia treatment in
             Western medicine or Traditional Chinese Medicine in the last 12 weeks;

          -  no informed consent obtained.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanfang Li, PhD</last_name>
    <phone>+86-20-36598857</phone>
    <email>gzyanfangli@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the first affiliated hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanfang Li, PhD</last_name>
      <phone>+86-20-36598857</phone>
      <email>gzyanfangli@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Voskaridou E, Balassopoulou A, Boutou E, Komninaka V, Christoulas D, Dimopoulou M, Delaki EE, Loukopoulos D, Terpos E. Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia center. Eur J Haematol. 2014 Dec;93(6):492-9. doi: 10.1111/ejh.12387. Epub 2014 Jun 26.</citation>
    <PMID>24889414</PMID>
  </reference>
  <reference>
    <citation>Costa D, Capuano M, Sommese L, Napoli C. Impact of epigenetic mechanisms on therapeutic approaches of hemoglobinopathies. Blood Cells Mol Dis. 2015 Aug;55(2):95-100. doi: 10.1016/j.bcmd.2015.05.004. Epub 2015 May 12. Review.</citation>
    <PMID>26142322</PMID>
  </reference>
  <reference>
    <citation>Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C; British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012 Mar;156(5):588-600. Erratum in: Br J Haematol. 2012 Aug;158(4):559.</citation>
    <PMID>22512001</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Yanfang Li</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 18, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

